Erica Weinstein

Erica Weinstein is a scientist entrepreneur and currently serves as Vice President, Flagship Labs Strategy & Development at Flagship Pioneering, driving initiatives related to origination and company growth and to establish and steward external partnerships. Her focus is on enhancing collaboration with Flagship-founded companies, optimizing value creation, and fostering growth across the Flagship Enterprise.

Previously, Erica led venture-creation efforts to found and grow companies based on new biotechnologies. She operated alongside a team to explore innovative ideas and spearhead the development of science, intellectual property, and business strategies that served as the foundation of groundbreaking startups. Erica co-founded and served as Head of Research at Ring Therapeutics, Laronde (now Sail Biomedicines), and ProFound Therapeutics and launched Sonata Therapeutics.

Before joining Flagship, Erica earned her doctorate in biomedical sciences from the Icahn School of Medicine at Mount Sinai. Her research focused on investigating the emerging role of the microbiome in the development of autoimmune diseases. During her studies, Erica was the recipient of the Helmsley Charitable Trust Fellowship and the Levine Foundation Fellowship Awards. Erica received her B.S. in biology with a minor in global health, culture, and society from Emory University.

Erica's work has resulted in numerous patents and publications. She was recognized in 2017 as a top female leader in Business Insider's “30 Biotech leaders under 40”, and, in 2021, she was featured in Business Insiders’ list of “12 young serial entrepreneurs” shaping the future of biotech startups. In 2023, Erica was honored as one of three trailblazing alumni from the Icahn School of Medicine at Mount Sinai.